TITLE:
Stratified Cox Regression Analysis of Survival under CIMAvax®EGF Vaccine
AUTHORS:
Carmen Viada Gonzalez, Jean-François Dupuy, Martha Fors López, Patricia Lorenzo Luaces, Camilo Rodríguez Rodríguez, Gisela González Marinello, Elia Neninger Vinagera, Beatriz García Verdecia, Bárbara Wilkinson Brito, Liana Martínez Pérez, Mayelin Troche de la Concepción, Tania Crombet-Ramos
KEYWORDS:
Stratified Cox Regression Model; Risk Factor; Non-Small Lung Cancer; Censored Data
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.8A,
August
16,
2013
ABSTRACT: Background: The
Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research,
development and manufacturing of biotechnological products. CIMAvax?EGF
is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). Purpose: The aim of this work is to
evaluate the effects of some potential prognostic factors on the overall
survival of patients treated with CIMAvax?EGF vaccine, based on data
collected in a phase II and a phase III clinical trials. Methods: The stratified Cox regression model is used to evaluate the
effects of these prognostic factors, based on separate analysis for each trial,
and on the combined data from both trials. Results: Patients with Performance
status 0 or 1, with IV stage of tumor and male under 60 years obtain more
benefit in terms of
overall survival if they receive CIMAvax?EGF. Conclusions: Vaccinated group has a better performance if patients have a performance status 0 or 1, stage IV and age
under 60 years. These prognostic factors influence overall survival in a positive
way for those patients that received CIMAvax?EGF.